CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
103.18
1.99%
Market Trading Hours* (UTC) Opens on Monday at 09:10

Mon: 09:10 - 00:00

Tue - Thu: 00:00 - 01:00 09:10 - 00:00

Fri: 00:00 - 01:00 09:10 - 22:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.53
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

BioNTech SE ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 101.17
Open* 100.95
1-Year Change* -37.92%
Day's Range* 100.79 - 103.52
52 wk Range 88.00-188.99
Average Volume (10 days) 405.14K
Average Volume (3 months) 13.98M
Market Cap 23.10B
P/E Ratio 7.92
Shares Outstanding 237.72M
Revenue 7.22B
EPS 12.26
Dividend (Yield %) N/A
Beta 0.25
Next Earnings Date Mar 25, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 8, 2023 103.18 1.67 1.65% 101.51 103.54 100.15
Dec 7, 2023 100.95 -0.08 -0.08% 101.03 101.90 98.95
Dec 6, 2023 100.95 2.79 2.84% 98.16 102.44 97.05
Dec 5, 2023 98.52 -0.57 -0.58% 99.09 100.11 97.63
Dec 4, 2023 97.86 -1.49 -1.50% 99.35 100.03 95.08
Dec 1, 2023 99.02 1.37 1.40% 97.65 99.46 94.61
Nov 30, 2023 99.61 -0.15 -0.15% 99.76 103.33 99.08
Nov 29, 2023 99.20 1.39 1.42% 97.81 101.95 97.81
Nov 28, 2023 98.25 2.13 2.22% 96.12 98.70 95.72
Nov 27, 2023 96.36 -2.37 -2.40% 98.73 99.71 96.36
Nov 24, 2023 98.58 1.30 1.34% 97.28 99.97 96.60
Nov 22, 2023 97.59 0.66 0.68% 96.93 98.19 95.65
Nov 21, 2023 96.74 -1.32 -1.35% 98.06 99.45 95.19
Nov 20, 2023 98.61 -0.28 -0.28% 98.89 99.60 98.24
Nov 17, 2023 99.25 -0.27 -0.27% 99.52 100.64 98.55
Nov 16, 2023 99.83 -0.16 -0.16% 99.99 100.31 98.11
Nov 15, 2023 100.47 -0.08 -0.08% 100.55 102.13 98.58
Nov 14, 2023 100.55 2.66 2.72% 97.89 101.59 96.69
Nov 13, 2023 97.78 -1.00 -1.01% 98.78 99.35 96.16
Nov 10, 2023 99.13 0.59 0.60% 98.54 100.46 97.56

BioNtech SE Events

Time (UTC) Country Event
Monday, March 25, 2024

Time (UTC)

12:30

Country

US

Event

Q4 2023 BioNTech SE Earnings Release
Q4 2023 BioNTech SE Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 17310.6 18976.7 482.325 108.589 127.575
Revenue 17310.6 18976.7 482.325 108.589 127.575
Cost of Revenue, Total 2995 2911.5 59.333 17.361 13.69
Gross Profit 14315.6 16065.2 422.992 91.228 113.885
Total Operating Expense 4667.9 3692.9 564.742 290.107 181.429
Selling/General/Admin. Expenses, Total 544.2 328.9 103.457 44.45 27.07
Research & Development 1487.7 916.3 614.837 197.893 124.728
Depreciation / Amortization 49.3 40.2 35.296 32.388 20.617
Unusual Expense (Income) -1.4 -137.2 0
Other Operating Expenses, Total -65 -1.1 -248.181 -1.985 -4.676
Operating Income 12642.7 15283.8 -82.417 -181.518 -53.854
Interest Income (Expense), Net Non-Operating 314.1 -215.5 -60.337 2.404 6.24
Other, Net -2.7 -21.9 -3.048 -0.326 -0.048
Net Income Before Taxes 12954.1 15046.4 -145.802 -179.44 -47.662
Net Income After Taxes 9434.4 10292.5 15.198 -179.172 -48.262
Minority Interest 0 0.116 0.243
Net Income Before Extra. Items 9434.4 10292.5 15.198 -179.056 -48.019
Net Income 9434.4 10292.5 15.198 -179.056 -48.019
Income Available to Common Excl. Extra. Items 9434.4 10292.5 15.198 -179.056 -48.019
Income Available to Common Incl. Extra. Items 9434.4 10292.5 15.198 -179.056 -48.019
Diluted Net Income 9434.4 10292.5 15.198 -179.056 -48.019
Diluted Weighted Average Shares 249.8 259.7 253.3 210.654 226.262
Diluted EPS Excluding Extraordinary Items 37.7678 39.6323 0.06 -0.85 -0.21223
Diluted Normalized EPS 37.7637 39.2709 0.06 -0.85 -0.21223
Interest Expense (Income) - Net Operating -341.9 -365.7
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 167.7 1277 4278.3 3461.2 3196.5
Revenue 167.7 1277 4278.3 3461.2 3196.5
Cost of Revenue, Total 162.9 96 183.5 752.8 764.6
Gross Profit 4.8 1181 4094.8 2708.4 2431.9
Total Operating Expense 731 622.6 985.4 1073.7 986.9
Selling/General/Admin. Expenses, Total 140.8 131.6 137.5 153.8 147.8
Research & Development 359.6 319.3 496.5 328.2 388
Depreciation / Amortization 13.8 14.7 13.3 13.6 11.6
Interest Expense (Income) - Net Operating 58.6 74.6 166.5 -166.4 -287.3
Unusual Expense (Income) -1.2 -0.2 0
Other Operating Expenses, Total -4.7 -13.6 -10.7 -8.1 -37.8
Operating Income -563.3 654.4 3292.9 2387.5 2209.6
Interest Income (Expense), Net Non-Operating 152.4 53.2 -120.3 56.7 109.7
Other, Net -1.3 0.1 0 -0.1 0
Net Income Before Taxes -412.2 707.7 3172.6 2444.1 2319.3
Net Income After Taxes -190.4 502.2 2278.7 1784.9 1672
Net Income Before Extra. Items -190.4 502.2 2278.7 1784.9 1672
Net Income -190.4 502.2 2278.7 1784.9 1672
Income Available to Common Excl. Extra. Items -190.4 502.2 2278.7 1784.9 1672
Income Available to Common Incl. Extra. Items -190.4 502.2 2278.7 1784.9 1672
Diluted Net Income -190.4 502.2 2278.7 1784.9 1672
Diluted Weighted Average Shares 241.013 244.97 244.761 255.716 259.225
Diluted EPS Excluding Extraordinary Items -0.79 2.05005 9.3099 6.98 6.45
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.79 2.05005 9.30638 6.97943 6.45
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 21922 15072.3 1666.9 560.151 448.961
Cash and Short Term Investments 14064.5 2074.3 1347.44 520.829 411.831
Cash 13875.1 1692.7 1210.21 519.149 411.495
Short Term Investments 189.4 381.6 137.234 1.68 0.336
Total Receivables, Net 7146 12382.1 170.521 20.205 28.44
Accounts Receivable - Trade, Net 7145.6 12381.7 165.468 11.913 18.938
Total Inventory 439.6 502.5 64.12 11.722 5.789
Prepaid Expenses 29.845 0.351 0.155
Other Current Assets, Total 271.9 113.4 54.967 7.044 2.746
Total Assets 23279.1 15830.8 2318.62 797.647 652.986
Property/Plant/Equipment, Total - Net 821.1 520.4 325.956 148.062 115.965
Property/Plant/Equipment, Total - Gross 937.4 594.6 384.288 197.345 152.617
Accumulated Depreciation, Total -116.3 -74.2 -58.332 -49.285 -36.652
Goodwill, Net 61.2 57.8 53.697 2.978 0.534
Intangibles, Net 158.5 144.6 109.793 86.456 87.508
Long Term Investments 80.2 21.3 0 0.018
Other Long Term Assets, Total 236.1 14.4 162.278 0
Total Current Liabilities 2950.6 3481.6 606.014 138.142 126.121
Accounts Payable 204.1 160 102.288 20.498 41.721
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 36 129.9 6.127 3.485 8.266
Other Current Liabilities, Total 2710.5 3191.7 497.599 114.159 76.134
Total Liabilities 3223.5 3937.1 946.774 304.155 386.833
Total Long Term Debt 176.2 171.6 231.047 68.904 5.6
Long Term Debt 2.1 17.9 153.016 14.777 5.6
Minority Interest 0 0.847
Other Liabilities, Total 90.5 217.2 109.432 97.109 254.265
Total Equity 20055.6 11893.7 1371.85 493.492 266.153
Common Stock 248.6 246.3 246.31 232.304 193.296
Retained Earnings (Accumulated Deficit) 19812.3 11651.2 1130.32 266.713 72.857
Total Liabilities & Shareholders’ Equity 23279.1 15830.8 2318.62 797.647 652.986
Total Common Shares Outstanding 243.215 242.521 241.521 226.78 226.262
Capital Lease Obligations 174.1 153.7 78.031 54.127
Treasury Stock - Common -5.3 -3.8 -4.789 -5.525
Deferred Income Tax 6.2 66.7 0.281
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 18749.1 19213.9 20086.1 21922 21268.8
Cash and Short Term Investments 15749.1 15557.3 12501.9 14064.5 13428.5
Cash 13495.8 14166.6 12143.9 13875.1 13423.7
Short Term Investments 2253.3 1390.7 358 189.4 4.8
Total Receivables, Net 2298.1 2995.4 6988.8 7146 7309.8
Accounts Receivable - Trade, Net 2008.8 2663.8 6456.2 7145.6 7309.4
Total Inventory 415.7 448.9 424.1 439.6 294.8
Other Current Assets, Total 286.2 212.3 171.3 271.9 235.7
Total Assets 22207.2 22225.6 22079 23279.1 22660.6
Property/Plant/Equipment, Total - Net 925.9 894 847.6 821.1 760.5
Intangibles, Net 665.5 501.4 378.6 219.7 226.2
Other Long Term Assets, Total 208.4 242 249.9 236.1 352.3
Total Current Liabilities 1807.2 1819 1550.9 2950.6 3957.7
Accounts Payable 222.7 228.6 29.9 204.1 296.5
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 40 38.6 37.4 36 37
Other Current Liabilities, Total 1544.5 1551.8 1483.6 2710.5 3624.2
Total Liabilities 2340.4 2319.1 1813.7 3223.5 4294.3
Total Long Term Debt 161.9 167.1 172.4 176.2 237
Long Term Debt 161.9 167.1 172.4 176.2 237
Deferred Income Tax 43.1 4.5 5.3 6.2 7
Other Liabilities, Total 328.2 328.5 85.1 90.5 92.6
Total Equity 19866.8 19906.5 20265.3 20055.6 18366.3
Common Stock 248.6 248.6 248.6 248.6 248.6
Retained Earnings (Accumulated Deficit) 19629 19666.7 20024.3 19812.3 18128
Treasury Stock - Common -10.8 -8.8 -7.6 -5.3 -10.3
Total Liabilities & Shareholders’ Equity 22207.2 22225.6 22079 23279.1 22660.6
Total Common Shares Outstanding 237.715 239.771 240.99 243.215 242.521
Long Term Investments 1292.7 1374.3 516.8 80.2 52.8
Goodwill, Net 365.6
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 12954.1 15046.4 -145.802 -179.44 -47.662
Cash From Operating Activities 13577.4 889.7 -13.474 -198.537 -58.877
Cash From Operating Activities 123.3 75.2 38.744 33.896 21.984
Non-Cash Items 247.6 -32.6 188.487 31.109 7.943
Cash Taxes Paid 4222.1 3457.9 -0.378 -0.122 0.304
Cash Interest Paid 21.5 12.2 3.628 2.044 1.769
Changes in Working Capital 252.4 -14199.3 -94.903 -84.102 -41.142
Cash From Investing Activities -35.3 -566.1 -144.848 -77.115 -66.452
Capital Expenditures -363.3 -154 -85.446 -71.08 -67.157
Other Investing Cash Flow Items, Total 328 -412.1 -59.402 -6.035 0.705
Cash From Financing Activities -1419.3 94.2 894.725 383.29 365.177
Issuance (Retirement) of Stock, Net -875.9 160.9 753.007 375.351 361.725
Issuance (Retirement) of Debt, Net -59.1 -66.7 141.718 7.939 3.452
Foreign Exchange Effects 59.6 64.7 -45.343 0.016 -0.459
Net Change in Cash 12182.4 482.5 691.06 107.654 239.389
Total Cash Dividends Paid -484.3
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 707.7 12954.1 9781.5 7337.4 5018.1
Cash From Operating Activities -677.4 13577.4 12748.2 7969.3 4050.2
Cash From Operating Activities 31.4 123.3 94.3 60.8 27.6
Non-Cash Items 54 247.6 -267.6 -438 -197
Cash Taxes Paid 844.9 4222.1 2834.7 2081.4 1290
Cash Interest Paid 1.2 21.5 16.5 12.2 6.4
Changes in Working Capital -1470.5 252.4 3140 1009.1 -798.5
Cash From Investing Activities -735.4 -35.3 125.7 209 287.4
Capital Expenditures -54.8 -363.3 -218.8 -136.2 -60.8
Other Investing Cash Flow Items, Total -680.6 328 344.5 345.2 348.2
Cash From Financing Activities -291.3 -1419.3 -1354.6 -701.2 80.3
Issuance (Retirement) of Debt, Net -9.3 -59.1 -50.1 -40.5 -30.2
Foreign Exchange Effects -27.1 59.6 211.7 165 53.5
Net Change in Cash -1731.2 12182.4 11731 7642.1 4471.4
Issuance (Retirement) of Stock, Net -282 -875.9 -820.2 -176.4 110.5
Total Cash Dividends Paid -484.3 -484.3 -484.3
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
AT Impf GmbH Corporation 44.0475 105613143 -501758 2022-12-31
Medine GmbH Corporation 17.2689 41405853 -100000 2022-12-31
Baillie Gifford & Co. Investment Advisor 3.1073 7450298 -90614 2023-06-30 LOW
PRIMECAP Management Company Investment Advisor 1.9435 4659853 85590 2023-06-30
Temasek Holdings Pte. Ltd. Sovereign Wealth Fund 1.8843 4518080 140058 2023-06-30 LOW
Flossbach von Storch AG Investment Advisor 1.4652 3513215 71468 2023-09-30 LOW
Sahin (Ugur MD) Individual Investor 1.314 3150649 3150649 2022-12-31
Huber (Christoph M.D.) Individual Investor 1.0898 2613019 610979 2022-12-31 LOW
Artisan Partners Limited Partnership Investment Advisor 0.8468 2030282 -580576 2023-06-30 LOW
Wolfgang (Jeggle Helmut) Individual Investor 0.6364 1525967 -400000 2022-12-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.6087 1459453 -3569 2023-06-30 LOW
Marett (Sean) Individual Investor 0.3913 938140 232204 2022-12-31 LOW
Capital World Investors Investment Advisor 0.3857 924680 -466048 2023-06-30 LOW
Tureci (Ozlem) Individual Investor 0.3809 913247 913247 2022-12-31
Poetting (Sierk) Individual Investor 0.3085 739784 213722 2022-12-31 LOW
Altrinsic Global Advisors, LLC Investment Advisor/Hedge Fund 0.2954 708393 159498 2023-06-30 LOW
ACATIS Investment Kapitalverwaltungsgesellschaft GmbH Investment Advisor 0.293 702592 0 2023-08-31 LOW
Baillie Gifford Overseas Ltd. Investment Advisor 0.2568 615712 37283 2023-08-31 LOW
DWS Investment GmbH Investment Advisor/Hedge Fund 0.2246 538522 -31992 2023-06-30 LOW
Gilder Gagnon Howe & Co. LLC Hedge Fund 0.1928 462278 6422 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Biontech SE Company profile

Discover the latest BioNTech stock price today with our interactive streaming chart.

Founded in 2008, BioNTech is an innovative biotechnology company from Germany, specialising in the research, development and producing of active individualised immunotherapies. The company adheres to a patient-specific approach to treatment of serious diseases, such as cancer.

BioNTech shares a vision that every patient’s tumour is unique. It means that each patient’s treatment should be individualised. To implement the scientists’ ideas into practice, BioNTech has developed pioneering therapeutics for cancer and other rare and infectious diseases.

Headquartered in Mainz, Germany, the company is aimed at becoming the world’s leading biotechnology company for individialised cancer treatment. By 2020, BioNTech had more than 440 patients treated across 17 tumour types. The company has more than 1,300 employees and seven pharmaceutical partners.

In August 2018, the company partnered with the US pharmaceutical giant Pfizer Inc to develop mRNA-based vaccines for preventing influenza. In September 2019, BioNTech started working on the development of tuberculosis and HIV programmes and preclinical vaccine and immunotherapy candidates for the prevention of tuberculosis and HIV infections under an agreement with the Bill & Melinda Gates Foundation.

BioNTech stock floated on the NASDAQ stock exchange through a $150m initial public offering (IPO) in October 2019. Since then the BNTX stock quote has been traded on the US market.

In November 2020, BioNTech and Pfizer triggered the strongest wave of optimism on the stock market after they announced that their Covid-19 vaccine showed 90 per cent effectiveness during the phase-three clinical trials. The BioNTech share price soared 14 per cent the day after the announcement.

In 2019, BioNTech reported total revenues of about €109m. According to the estimates from Morgan Stanley, BioNTech and Pfizer can make around $13bn from vaccine sales, getting $6.5bn each if these estimates are correct.

Looking closely at the BioNTech stock price chart in 2020, we can see that BNTX stock has been trading in a range of $18.60-$115. Since the large sell-off in March 2020, the BioNTech SE (BNTX) stock quote grew from $28.55 on March 12, 2020, to $112.76 on November 10, 2020, which is a growth of 294 per cent.

Follow the BioNTech share price live on our interactive share price chart and build your own forecast for the famous German biotechnology company. Follow the latest BioNTech share news and spot the best levels to open profitable CFD trades at Capital.com.

Industry: Bio Therapeutic Drugs

An der Goldgrube 12
MAINZ
RHEINLAND-PFALZ 55131
DE

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

US100

16,080.90 Price
+0.500% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

XRP/USD

0.67 Price
-0.850% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Gold

2,004.85 Price
-1.180% 1D Chg, %
Long position overnight fee -0.0198%
Short position overnight fee 0.0116%
Overnight fee time 22:00 (UTC)
Spread 0.50

BTC/USD

43,970.10 Price
-0.160% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00
video

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading